# ADR 516 — Enterprise Biotechnology Bio Innovation Intelligence Platform (P217-Q)

## Status

Accepted

## Context

P217-P established biotechnology marketplace intelligence. P217-Q defines Bio Innovation Ecosystem: research network, scientific collaboration intelligence, innovation acceleration, innovation knowledge graph and digital twin — before Bio Investment (P217-R).

## Decision

1. SoR remains `biotechnology` / `CAP-PLT-BIO-001` for innovation *intelligence*.
2. Fabric: `meos_bio_innovation_intelligence_fabric`.
3. API: `/api/v1/biotechnology/bio-innovation*`.
4. Six innovation layers; research network, collaboration, acceleration, KG, and twin platforms.
5. All inference via P214-Z ACL only — `no_module_local_llm`.
6. Human innovation oversight and IP protection controls mandatory; never unverified innovation release.
7. Twins via P217-G; drug discovery via P217-K; manufacturing via P217-L; regulatory via P217-N; marketplace via P217-P; robotics via P216-Z; quantum via P215-Z.
8. Never replace Core, AI, Quantum, Robotics, hospital EMR, LIMS, pharmacy, prior P217 fabrics including Bio Marketplace.
9. Foundation for P217-R.

## Consequences

Positive: governed innovation ecosystem layer for investment and bio-security phases.  
Negative: collaboration / twin catalogs must stay aligned as autonomous research systems deepen.

## Alternatives rejected

- Sibling `bio_innovation` BC owning unrelated Core capabilities.
- Module-local LLM or releasing innovations without scientific verification.
- Merging peer SoRs (EMR/LIMS/pharmacy) into biotechnology without ACL peers.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_BIO_INNOVATION.md` · Prior: ADR 499–515 · Next: P217-R
